Immupharma Share Discussion Threads

[pwhite73] 03/5/2022 13:44

Lupuzor may well be making progress towards FDA approval but the company along with Lanstead are bleeding retail shareholders dry with this Share Agreement which is nothing more than death spiral in disguise.

[pwhite73] 29/4/2022 13:13

Note the way they lower the bid to make Lanstead sells look like buys.

[ascov] 28/4/2022 20:05

hi

2 points here:
1/ if the Company doesn't think it works (and they should know) why are they persisting ?
2/ Alternatively, there is the parable of the 'keys in the Drawer' : you always put your keys in the drawer. One day you go to get your keys, but they are not in there . You search the house, can't find them so go back and look in the drawer...guess what ? they are still not in there !
This parable reflects the human condition...particularly in relation to speculative investors.......

[pwhite73] 28/4/2022 13:49

Until there is news Lanstead will continue to trash the stock with the terms of the Share Agreement.

[pwhite73] 28/4/2022 13:28

In no way does it effect Lupuzor. TLR7 and its correlation with Lupus has been known for decades. The cost of gene therapy to cure mutated or faulty genes is the issue here. A single dose can cost anything up to £2 million. Its non-commercial at the moment.



"A Tlr7 translocation accelerates systemic autoimmunity in murine lupus" - June 27, 2006 "

[supernumerary] 28/4/2022 09:20

OK, thanks Nobby - thought it was worth asking the question!

[nobbygnome] 28/4/2022 08:54

Tlr-7 detects viral RNA whereas IMM are choosing patients on the basis of anti-DNA antibodies so no relevance here!

[sclper] 28/4/2022 08:49

Hopefully this discovery leads to a more effective treatment/cure for those suffering from Lupus:'The researchers are now working with pharmaceutical companies to explore the development of, or the repurposing of existing treatments, which target the TLR7 gene. And they hope that targeting this gene could also help patients with related conditions.Carola adds: "There are other systemic autoimmune diseases, like rheumatoid arthritis and dermatomyositis, which fit within the same broad family as lupus. TLR7 may also play a role in these conditions."Carola has started a new laboratory at the Francis Crick Institute to further understand the disease-causing mechanisms that occur downstream of key mutations like the one found on the TLR7 gene.' 

[supernumerary] 28/4/2022 08:34

Interesting discussion of this discovery from the Crick Institute:

I wonder if this can throw any light on the biomarkers IMM are planning to use?

[sclper] 28/4/2022 08:20

Lupus gene discovery brings cure hope to Britain's 50,000 sufferersScientists found that a single mutation in the TLR7 gene drives the condition, and are now searching for a drug that could fix the defect.Scientists at London's Francis Crick Institute found that a single mutation in the TLR7 gene can drive the condition, and have started working with pharmaceutical companies to find drugs that could fix the defect.

[bobdown2] 27/4/2022 15:42

Premiums being paid now.??

[tomboyb] 26/4/2022 15:40

Technically I'm correct -

But I understand where you are coming from -

lol -

[pwhite73] 26/4/2022 15:32

You want premiums paid on higher share prices not lower share prices.

[tomboyb] 26/4/2022 14:42

Premiums paid now -

[tomboyb] 26/4/2022 12:01

Correct Pwhite -

Obviously with no vol the price will fall -

The volume has been there not just now. Confirmation of Phase III and we are off -

[pwhite73] 26/4/2022 11:59

Yes but when there are no buyers at 8p the MM have to lower the price to 7.5p to attract buyers. When there are no buyers 7.5p the MM have to lower the price to 7p to attract buyers. When there are no buyers 7p the MM have to lower the price to 6.5p to attract buyers and so forth. That's what's going on.

[tomboyb] 26/4/2022 11:44

£91k works out around 1.4mill shares-

So not much at these levels -

[lse2020] 26/4/2022 10:54

6p coming then

[pwhite73] 26/4/2022 09:55

tomboyb - That's because Lanstead are trashing the shares everyday as part of the Share Agreement (RNS 20/12/2021). Lanstead has invested £2.2 million in the company and can recover their investment by selling £91,667 worth of shares every month for a 24 month period. That's why no rises can be held onto at the moment.

Avion are funding the P3 trials for up to $25 million. This money is nothing to do with IMM they see none of it.

The plan is when the P3 trials start and other commercial partnerships are announced the current market cap and share price will be a distant memory and the Lanstead monthly sales of £91,667 which is peanuts will have no effect on the share price. However in the absence of any positive news the Lanstead sells everyday are dragging the price down as there are no buyers at the moment until further news is announced.

[tomboyb] 26/4/2022 09:01

6.4p on offer -

A far cry from over 9p+ a couple weeks ago -

[officerdigby] 24/4/2022 23:56

PWhite73 - pro (currently tiny) biotech company...

..worlds twisted on its head.

[thordon] 24/4/2022 14:30

SYME is just a con same as INSP